Capsugel focusing on inhaled biotherapeutics from Bend facility

Capsugel is formulating biotherapeutics to be delivered into the lungs

Capsugel says it is bolstering its service to offer specialised dry powder inhalation (DPI) formulations, allowing biotherapeutics to be delivered to the lung rather than by injection.

The dosage forms solutions company has completed the manufacture of Phase II supplies of an inhalation delivery therapy from its clinical trial manufacturing (CTM) facility in Bend, Oregon.

While the Capsugel could not disclose the customer nor the molecule, David Lyon, Head of Biotherapeutic Formulation and Processing, told us this was the first time the plant has manufactured an inhaled dry-powder biotherapeutic to Phase II scale, and could demonstrated the advances in such technology.

"The industry has advanced substantially in delivery of large molecules to the lung using differentiated technologies," he explained. "The key challenge that we have addressed is the ability to engineer the particle for lung delivery rather than via injection."

Capsugel acquired the facility when it bought Bend Research in 2013, and Lyon said the combined entity now has "expertise in spray-dried dispersion technology," meaning the firm can now manufacture engineered particles for efficient delivery to the lung.

"By advancing our offering to include specialized DPI capsules and now clinical manufacturing supplies for biotherapeutic compounds, we are bolstering our ability to help customers bring these innovative therapies to market to benefit patients."

Capsugel invested $20m in Bend in November 2013 to add commercial spray drying capacity, and Lyon siad this will be coming online later this year. "We will soon be able to manufacture at commercial scale for DPI formulations as well."

Related News

Serendex is developing an inhalable biopharmaceutical for rare lung diseases. (Image of heart and lungs: University of Liverpool Medical Archives)

Inhalable biologics: Serendex formulates with Novozymes’ Recombumin

Capsugel acquired Oregon-based bioavailability enhancement firm Bend Research in 2013

Capsugel completes $25m SDD expansion at Bend site

Image: iStock/janulla

Capsugel: Pulmatrix deal brings us to ‘the forefront of inhalation delivery’


MPA withdraws Bend's Oregon plant GMP certificate citing deficiencies


Lonza to buy Capsugel for $5.5bn, no site divestitures planned

Image: iStock/beltado

H&T Presspart buys rights to Hovione inhaler tech

New DFS Unit Built on Technology, R&D and Manufacturing, says Capsugel

New DFS Unit Built on Technology, R&D and Manufacturing, says Capsugel

Capsugel site in Colmar, France

Capsugel’s French and Belgian Sites Receive EXCiPACT Certification

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Three Capsugel plants have seen recent expansions

Capsugel expands manufacturing capacity at three FDF plants

Capsugel Buys Encap Drug Delivery

Capsugel Buys Encap as Part of Dosage Form Solution Strategy

Related Products

See more related products